Skip to main content
VTGN
NASDAQ Life Sciences

FDA Clears Vistagen's Refisolone for U.S. Phase 2 Trials

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.59
Mkt Cap
$23.637M
52W Low
$0.43
52W High
$5.14
52W Position info
37% above low
Off High info
89% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

VTGN sits 37% above its 52-week low of $0.43.

Summary

Vistagen Therapeutics has received an FDA "Study May Proceed" letter for its refisolone nasal spray, enabling the company to advance the non-hormonal candidate into U.S. Phase 2 clinical trials for menopausal hot flashes. This positive regulatory milestone is highly significant for a small biotech company, especially one facing substantial doubt about its ability to continue as a going concern and a Nasdaq delisting threat, as highlighted in its recent 10-Q. The news follows promising exploratory Phase 2a results from Mexico, where refisolone demonstrated an 80% reduction in hot flash frequency versus 36% for placebo. Advancing a drug candidate to U.S. Phase 2 provides a critical potential path to future revenue and could materially impact the company's long-term viability and investor sentiment. Traders will closely monitor the initiation and progress of these U.S. trials.

At the time of this announcement, VTGN was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6M. The 52-week trading range was $0.43 to $5.14. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

VTGN - Latest Insights

VTGN
Nov 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.172
Real-time Price: $0.186723 info
Change: +$0.014723 (+9%) info
Market Cap: $8.183M info
VTGN
Oct 30, 2026, 5:24 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.1714
Real-time Price: $0.186723 info
Change: +$0.015323 (+9%) info
Market Cap: $8.183M info
VTGN
Oct 09, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.2461
Real-time Price: $0.186723 info
Change: -$0.059377 (-24%) info
Market Cap: $8.183M info
VTGN
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.373
Real-time Price: $0.186723 info
Change: -$0.186277 (-50%) info
Market Cap: $8.183M info
VTGN
Sep 22, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.2644
Real-time Price: $0.186723 info
Change: -$0.077677 (-29%) info
Market Cap: $8.183M info